154057-58-6 Usage
Description
[2-Cyclopropyl-4-(4-fluorophenyl)-quinolin-3-ylmethyl]-triphenyl-phosphonium bromido is a complex organic compound with a unique chemical structure. It is characterized by its quinolinyl core, which is substituted with a cyclopropyl group at the 2nd position and a 4-fluorophenyl group at the 4th position. The molecule is further modified by a triphenyl-phosphonium bromide group attached to the quinolinyl core. [2-Cyclopropyl-4-(4-fluorophenyl)-quinolin-3-ylmethyl]-triphenyl-phosphonium bromido is known to be an impurity derived from the synthesis of HMG-CoA reductase inhibitor Pitavastatin, a widely used drug for treating high cholesterol and related cardiovascular conditions.
Uses
Used in Pharmaceutical Industry:
[2-Cyclopropyl-4-(4-fluorophenyl)-quinolin-3-ylmethyl]-triphenyl-phosphonium bromido is used as an impurity in the synthesis of HMG-CoA reductase inhibitors, specifically Pitavastatin. Its presence in the synthesis process is crucial for the development of this class of cholesterol-lowering drugs, which are essential for managing high cholesterol levels and reducing the risk of cardiovascular diseases.
Used in Research and Development:
[2-Cyclopropyl-4-(4-fluorophenyl)-quinolin-3-ylmethyl]-triphenyl-phosphonium bromido can also be utilized in research and development settings, where it may serve as a starting material or a reference compound for the synthesis of novel HMG-CoA reductase inhibitors or other related pharmaceuticals. Its unique structure and properties make it a valuable tool for exploring new drug candidates and understanding the mechanisms of action of existing cholesterol-lowering agents.
Used in Quality Control and Analysis:
In the pharmaceutical industry, [2-Cyclopropyl-4-(4-fluorophenyl)-quinolin-3-ylmethyl]-triphenyl-phosphonium bromido can be employed as a reference compound for quality control and analysis purposes. Its presence in the synthesis of Pitavastatin and other HMG-CoA reductase inhibitors can be monitored and controlled to ensure the purity and efficacy of the final drug product. This helps maintain the safety and effectiveness of these medications for patients.
Check Digit Verification of cas no
The CAS Registry Mumber 154057-58-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,4,0,5 and 7 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 154057-58:
(8*1)+(7*5)+(6*4)+(5*0)+(4*5)+(3*7)+(2*5)+(1*8)=126
126 % 10 = 6
So 154057-58-6 is a valid CAS Registry Number.
154057-58-6Relevant articles and documents
A novel preparation method of a pitavastatin calcium intermediate
-
Paragraph 0021-0032, (2019/07/11)
The invention relates to a preparation method of [[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]methyl]triphenylphosphonium bromide, comprising the following steps: reacting 2-Cyclopropyl-4-(4-fluorophenyl)-quinolyl-3-methanol and triphenylphosphine hydrobromide in an organic solvent to obtain a target compound. The preparation method provided by the invention has the advantages of easily available raw materials, simple operation and high yield, effectively reduces phosphorus-containing wastewater and phosphorus-containing waste residues, reduces the production cost, and is beneficial to large-scale production.
Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof
-
, (2012/02/01)
Processes for preparing pravastatin, intermediates and pharmaceutically acceptable salts thereof are provided Crystalline forms of pravastatin, intermediates and pharmaceutically acceptable salts thereof are also disclosed.
METHOD FOR PREPARATION OF PITAVASTATIN AND ITS PHARMACEUTICAL ACCEPTABLE SALTS THEREOF
-
Page/Page column 9-10, (2012/02/03)
The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium.